HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

Files in This Item:
BJC95-8.pdf1.1 MBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/21810

Title: A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations
Authors: Asahina, H. Browse this author
Yamazaki, K. Browse this author
Kinoshita, I. Browse this author
Sukoh, N. Browse this author
Harada, M. Browse this author
Yokouchi, H. Browse this author
Ishida, T. Browse this author
Ogura, S. Browse this author
Kojima, T. Browse this author
Okamoto, Y. Browse this author
Fujita, Y. Browse this author
Dosaka-akita, H. Browse this author
Isobe, H. Browse this author
Nishimura, M. Browse this author →KAKEN DB
Keywords: gefitinib
non-small cell lung cancer (NSCLC)
epidermal growth factor receptor (EGFR)
mutation
first-line therapy
Issue Date: 23-Oct-2006
Publisher: Nature Publishing Group
Journal Title: British Journal of Cancer
Volume: 95
Issue: 8
Start Page: 998
End Page: 1004
Publisher DOI: 10.1038/sj.bjc.6603393
PMID: 17047648
Abstract: Retrospective analysis has shown that activating mutations in exons 18-21 of the epidermal growth factor receptor (EGFR) gene are a predictor of response to gefitinib. We conducted a phase II trial to evaluate the efficacy and safety of gefitinib as first-line therapy for advanced non-small cell lung cancer (NSCLC) with EGFR mutations. Patients with stage IIIB or IV chemotherapy-naïve NSCLC with EGFR mutation were treated with 250 mg gefitinib daily. For mutational analysis, DNA was extracted from paraffin-embedded tissues and EGFR mutations were analysed by direct sequence of PCR products. Twenty (24%) of the 82 patients analysed had EGFR mutations (deletions in or near E746-A750, n=16; L858R, n=4). Sixteen patients were enrolled and treated with gefitinib. Twelve patients had objective response and response rate was 75% (95% CI, 48-93%). After a median follow-up of 12.7 months (range, 3.1-16.8 months), 10 patients demonstrated disease progression, with median progression-free survival of 8.9 months (95% CI, 6.7-11.1 months). The median overall survival time has not yet been reached. Most of the toxicities were mild. This study showed that gefitinib is very active and well tolerated as first-line therapy for advanced NSCLC with EGFR mutations.
Rights: Nature Publishing Group, BRITISH JOURNAL OF CANCER, Vol. 95, issue 8, 2006, pp. 998-1004
Relation: http://npg.nature.com/npg/servlet/Content?data=xml/02_welcome.xml&style=xml/02_welcome.xsl
Type: article (author version)
URI: http://hdl.handle.net/2115/21810
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 山崎 浩一

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

 - Hokkaido University